Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study

PaperCitations, authors & open-access status

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 135 citations, 2019 year and closed oa status.

135
Citations
2019
Year
closed
OA Status

Related on ScholarIQ

Fang Liu
Author
The Lancet Respiratory Medicine
Journal
Cystic Fibrosis Research Advances
Topic
Cystic Fibrosis Research Advances
Topic
Pediatric health and respiratory diseases
Topic
Immunodeficiency and Autoimmune Disorders
Topic
470M+ articles · free account